| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 10/02/2023 | SOLENO THERAPEUTICS INC | SLNO | Exercise (in-the-money or at-the-money) | Tranche B Warrants (right to buy) | 5.2M | $2.50 | $13M | By Vivo Opportunity Fund Holdings, L.P. | 10/02/2023 |
| 09/26/2023 | SOLENO THERAPEUTICS INC | SLNO | Exercise (in-the-money or at-the-money) | Tranche A Warrants (right to buy) | 3.2M | $1.75 | $5.6M | By Vivo Opportunity Fund Holdings, L.P. | 09/26/2023 |
| 09/07/2022 | Terns Pharmaceuticals, Inc. | | Purchase | Common Stock | 600k | $3.60 | $2.2M | By Vivo Opportunity Fund Holdings, L.P. | 09/07/2022 |
| 08/16/2022 | Terns Pharmaceuticals, Inc. | | Purchase | Pre-funded Warrants (right to buy) | 1.5M | $0.00 | $150 | By: Vivo Opportunity Fund Holdings, L.P. | 08/12/2022 |
| 08/16/2022 | Terns Pharmaceuticals, Inc. | | Purchase | Common Stock | 1.5M | $2.42 | $3.6M | By: Vivo Opportunity Fund Holdings, L.P. | 08/12/2022 |
| 08/15/2022 | Terns Pharmaceuticals, Inc. | | Purchase | Common Stock | 1.2k | $2.99 | $3.6k | By: Vivo Opportunity Fund Holdings, L.P. | 08/12/2022 |
| 08/12/2022 | Terns Pharmaceuticals, Inc. | | Purchase | Common Stock | 1.1M | $2.98 | $3.3M | By Vivo Opportunity Fund Holdings, L.P. | 08/12/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Common Stock | 161.7k | $55.00 | $8.9M | By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. | 07/01/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Common Stock | 2.7M | $55.00 | $150.5M | By: Vivo Opportunity Fund Holdings, L.P. | 07/01/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Common Stock | 431.9k | $55.00 | $23.8M | By: Vivo Capital Fund IX, L.P. | 07/01/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Series A Warrants | 324.7k | $13.20 | $4.3M | By: Vivo Capital Fund IX, L.P. | 07/01/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Series A Warrants | 1.5M | $13.20 | $19.2M | By: Vivo Opportunity Fund Holdings, L.P. | 07/01/2022 |
| 07/01/2022 | Sierra Oncology, Inc. | SRRA | Disposition | Series A Warrants | 75.7k | $13.20 | $999.9k | By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. | 07/01/2022 |
| 01/31/2022 | Sierra Oncology, Inc. | SRRA | Purchase | Common Stock | 800k | $27.00 | $21.6M | By Vivo Opportunity Fund, L.P. | 01/31/2022 |
| 01/26/2022 | Sierra Oncology, Inc. | SRRA | Exercise (in-the-money or at-the-money) | Series B Warrant (Right to Purchase ) | 75.7k | $13.20 | $999.9k | By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. | 01/26/2022 |
| 01/26/2022 | Sierra Oncology, Inc. | SRRA | Exercise (in-the-money or at-the-money) | Series B Warrant (Right to Purchase ) | 1.5M | $13.20 | $19.2M | By: Vivo Opportunity Fund, L.P. | 01/26/2022 |
| 01/26/2022 | Sierra Oncology, Inc. | SRRA | Exercise (in-the-money or at-the-money) | Series B Warrant (Right to Purchase ) | 324.7k | $13.20 | $4.3M | By: Vivo Capital Fund IX, L.P. | 01/26/2022 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Common Stock | 75.8k | $0.00 | $0 | By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. | 01/29/2020 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Common Stock | 1.5M | $0.00 | $0 | By Vivo Opportunity Fund, L.P. | 01/29/2020 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Common Stock | 324.8k | $0.00 | $0 | By: Vivo Capital Fund IX, L.P. | 01/29/2020 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Series A Convertible Voting Preferred Stock | 1000 | $0.00 | $0 | By: Vivo Ventures Fund VII, L.P. and Vivo Ventures VII Affiliates Fund, L.P. | 01/29/2020 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Series A Convertible Voting Preferred Stock | 19.2k | $0.00 | $0 | By Vivo Opportunity Fund, L.P. | 01/29/2020 |
| 01/29/2020 | Sierra Oncology, Inc. | SRRA | Conversion | Series A Convertible Voting Preferred Stock | 4.3k | $0.00 | $0 | By: Vivo Capital Fund IX, L.P. | 01/29/2020 |